Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
However, no association was observed between OMD and Ca2+ or 25-hydroxyvitamin D (25-OH) (Fig. 1j and Supplementary Fig. 1a).
Source: OMD decreases in osteoporosis and is negatively correlated with bone loss. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
DMP1-cre transgenic mice were a gift from Dr.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Osteoblast-derived osteomodulin restrains osteoclastogenesis via ITGB8/RRM2-mediated reduction of mitochondrial respiration and mitochondrial ATP production
Study design awaiting verification · Experimental & Molecular Medicine · 2026
Original publication title
Osteoblast-derived osteomodulin restrains osteoclastogenesis via ITGB8/RRM2-mediated reduction of mitochondrial respiration and mitochondrial ATP production
© The Author(s) 2026
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Osteoporosis is driven in part by excessive osteoclast-mediated bone resorption, yet osteoblast-derived extracellular cues that restrain osteoclast bioenergetics remain incompletely defined. Here we identify osteomodulin (OMD), a matrix-associated osteoblast-derived protein that is reduced in the bone tissue and serum of postmenopausal patients with osteoporosis. Inducible global or osteoblast-specific Omd deletion exacerbates bone loss and increases osteoclast activity, whereas osteoclast precursor-specific deletion produces no overt skeletal phenotype. Mechanistically, OMD engages integrin β8 on osteoclast precursors, suppresses RhoA activity and enhances YAP phosphorylation, thereby reducing YAP/TEAD occupancy at the ribonucleotide reductase M2 (RRM2) promoter and repressing Rrm2 transcription.
Consistent with RRM2’s role in maintaining the dNTP pools required for mitochondrial DNA replication, OMD decreases mtDNA copy number and the abundance of electron transport chain proteins, leading to reduced mitochondrial respiration and ATP production, with only limited glycolytic compensation. Finally, recombinant OMD supplementation or pharmacologic RRM2 inhibition mitigates ovariectomy and lipopolysaccharide-induced bone loss. Together, our findings identify an OMD-integrin β8-RhoA-YAP/TEAD-RRM2 axis that links extracellular matrix signaling to mitochondrial respiration and mitochondrial ATP production during osteoclastogenesis.
Osteomodulin links bone loss to mitochondrial function
Osteoporosis is a condition characterized by reduced bone strength, increasing the risk of fractures, particularly in older adults and postmenopausal women. This study explores a protein called osteomodulin (OMD) and its role in bone health. Researchers found that OMD levels are lower in people with osteoporosis. They used mice to study how OMD affects bone cells. By removing OMD in mice, they observed increased bone loss and more active bone-resorbing cells called osteoclasts. They also discovered that OMD interacts with a receptor called ITGB8 on osteoclast precursors, reducing their activity by affecting energy production in the cells.
The study suggests that OMD helps maintain bone health by regulating osteoclast activity. The researchers propose that increasing OMD levels or targeting related pathways could be a new way to treat osteoporosis.
This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
Authors’ abstract
Osteoporosis is driven in part by excessive osteoclast-mediated bone resorption, yet osteoblast-derived extracellular cues that restrain osteoclast bioenergetics remain incompletely defined. Here we identify osteomodulin (OMD), a matrix-associated osteoblast-derived protein that is reduced in the bone tissue and serum of postmenopausal patients with osteoporosis. Inducible global or osteoblast-specific Omd deletion exacerbates bone loss and increases osteoclast activity, whereas osteoclast precursor-specific deletion produces no overt skeletal phenotype. Mechanistically, OMD engages integrin β8 on osteoclast precursors, suppresses RhoA activity and enhances YAP phosphorylation, thereby reducing YAP/TEAD occupancy at the ribonucleotide reductase M2 (RRM2) promoter and repressing Rrm2 transcription.
Consistent with RRM2’s role in maintaining the dNTP pools required for mitochondrial DNA replication, OMD decreases mtDNA copy number and the abundance of electron transport chain proteins, leading to reduced mitochondrial respiration and ATP production, with only limited glycolytic compensation. Finally, recombinant OMD supplementation or pharmacologic RRM2 inhibition mitigates ovariectomy and lipopolysaccharide-induced bone loss. Together, our findings identify an OMD-integrin β8-RhoA-YAP/TEAD-RRM2 axis that links extracellular matrix signaling to mitochondrial respiration and mitochondrial ATP production during osteoclastogenesis.
Osteomodulin links bone loss to mitochondrial function
Osteoporosis is a condition characterized by reduced bone strength, increasing the risk of fractures, particularly in older adults and postmenopausal women. This study explores a protein called osteomodulin (OMD) and its role in bone health. Researchers found that OMD levels are lower in people with osteoporosis. They used mice to study how OMD affects bone cells. By removing OMD in mice, they observed increased bone loss and more active bone-resorbing cells called osteoclasts. They also discovered that OMD interacts with a receptor called ITGB8 on osteoclast precursors, reducing their activity by affecting energy production in the cells.
The study suggests that OMD helps maintain bone health by regulating osteoclast activity. The researchers propose that increasing OMD levels or targeting related pathways could be a new way to treat osteoporosis.
This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
Publication and source details
Original title: Osteoblast-derived osteomodulin restrains osteoclastogenesis via ITGB8/RRM2-mediated reduction of mitochondrial respiration and mitochondrial ATP production
Xiaowen Jiang; Han Chen; Weiduo Hou; Chengxin Dai; Ruijie Zhang; Erman Chen; Jingjing Zhang; Wanyi Wu; Jianbin Xu; Mo Chen; Liang Liu; Xun Tan; Xiaoxiao Ji; Xiaoyong Wu; Kanbin Wang; Chaorong Yu; Xiaohua Yu; Weixu Li; Wei Zhang
Experimental & Molecular Medicine · 2026
© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Key R&D Program of the China Ministry of Science and Technology (2024YFC2510600)the National Natural Science Foundation of China (No. 82002332)the National Natural Science Foundation of China (No. 82200995)the Postdoctoral Fellowship Program of CPSF (No. GZC20241495)Key R&D Program of the China Ministry of Science and Technology (2024YFC2510600) Zhejiang Provincial Key Research and Development Project (No. 2025C02168) the National Natural Science Foundation of China (No. 82272525)Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T23:45:20.067256+00:00
DOI: 10.1038/s12276-026-01682-7 · PMC13049008